Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib in CML-CP Previously Treated With 2 or More TKIs
NCT04948333Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2021
- Primary completion
- Mar 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 16
01
Overview
A Phase 3 trial of asciminib in chronic myelogenous leukemia (CML), sponsored by Novartis. Started Oct 2021; status: completed.
02
Drugs
asciminib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT04948333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04948333.